期刊
RSC MEDICINAL CHEMISTRY
卷 11, 期 6, 页码 665-675出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0md00049c
关键词
-
资金
- Swiss National Science Foundation
- Swiss Cancer League (Krebsliga)
- UZH Entrepreneur Fellowship in Biotechnology
The X-ray structure of the catalytic domain of the EphA3 tyrosine kinase in complex with a previously reported type II inhibitor was used to design two novel quinoxaline derivatives, inspired by kinase inhibitors that have reached clinical development. These two new compounds were characterized by an array of cell-based assays and gene expression profiling experiments. A global chemical proteomics approach was used to generate the drug-protein interaction profile, which suggested suitable therapeutic indications. Both inhibitors, studied in the context of angiogenesis andin vivoin a relevant lymphoma model, showed high efficacy in the control of tumor size.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据